Dr. Ehrin Armstrong presented the interim results from the first 752 patients in the Disrupt PAD III Observational Study (OS), reinforcing the consistency of IVL's unique mechanism of action to safely and effectively modify superficial and deep calcium across multiple vessel beds, lesion types and CLI patients.
This is the largest angiographic core lab adjudicated ‘real world’ evidence for IVL treatment of heavily calcified peripheral arteries with results comparable to the previously reported Disrupt PAD III Randomized Control Trial.
Listen to Dr. Armstrong’s thoughts on the results. Then take a deeper dive into the data and see how IVL is consistent in real world practice.
Download Dr. Ehrin Armstrong's Disrupt PAD III OS 752 LBCT slides here.
For more Shockwave IVL news & clinical evidence, follow @ShockwaveIVL on Twitter.
Important Safety Information
Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.
Indication for Use – The Shockwave Medical Intravascular Lithotripsy (IVL) System is intended for lithotripsy-enhanced balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. Not for use in the coronary or cerebral vasculature.
Contraindications – Do not use if unable to pass 0.014 guidewire across the lesion • Not intended for treatment of in-stent restenosis or in coronary, carotid, or cerebrovascular arteries.
Warnings – Only to be used by physicians who are familiar with interventional vascular procedures • Physicians must be trained prior to use of the device • Use the Generator in accordance with recommended settings as stated in the Operator’s Manual
Precautions – Use only the recommended balloon inflation medium • Appropriate anticoagulant therapy should be administered by the physician • Decision regarding use of distal protection should be made based on physician assessment of treatment lesion morphology
Adverse Effects – Possible adverse effects consistent with standard angioplasty include: • Access site complications • Allergy to contrast or blood thinners • Arterial bypass surgery • Bleeding complications • Death • Fracture of guidewire or device • Hypertension/Hypotension • Infection/sepsis • Placement of a stent • Renal failure • Shock/pulmonary edema • Target vessel stenosis or occlusion • Vascular complications. Risks unique to the device and its use: • Allergy to catheter material(s) • Device malfunction or failure • Excess heat at target site
Prior to use, please reference the Instructions for Use for more information on indications, contraindications, warnings, precautions, and adverse events. www.shockwavemedical.com
